Research Article
Impact of Interstitial Pneumonia on the Survival and Risk Factors Analysis of Patients with Hematological Malignancy
Table 6
Reviews of patients with HM and chemotherapy-related IP.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DLBCL: diffuse large B-cell lymphoma; ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; R-CHOP: rituximab, cyclophosphamide, epirubicin, vincristine, and prednisone; CHOP: cyclophosphamide, epirubicin, vincristine, and prednisone; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; NSIP: nonspecific interstitial pneumonia; BOOP: bronchiolitis obliterans organizing pneumonia. |